FI955261A0 - P-selectin antibodies and their use - Google Patents

P-selectin antibodies and their use

Info

Publication number
FI955261A0
FI955261A0 FI955261A FI955261A FI955261A0 FI 955261 A0 FI955261 A0 FI 955261A0 FI 955261 A FI955261 A FI 955261A FI 955261 A FI955261 A FI 955261A FI 955261 A0 FI955261 A0 FI 955261A0
Authority
FI
Finland
Prior art keywords
selectin antibodies
antibodies
selectin
activated
leukocytes
Prior art date
Application number
FI955261A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI955261A (en
Inventor
Robert W Chesnut
Margaret J Polley
James C Paulson
S Tarran Jones
Jose W Saldanha
Mary M Bendig
Michael Kriegler
Carl Perez
Robert Bayer
Michael Nunn
Original Assignee
Cytel Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1993/004274 external-priority patent/WO1993021956A1/en
Priority claimed from US08/202,047 external-priority patent/US5800815A/en
Application filed by Cytel Corp filed Critical Cytel Corp
Publication of FI955261A0 publication Critical patent/FI955261A0/en
Publication of FI955261A publication Critical patent/FI955261A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Abstract

The present invention relates to compositions and methods for treating inflammation and other pathological conditions using novel blocking P-selectin antibodies that inhibit adhesion of leukocytes to activated platelets and/or to activated vascular endothelium in vivo. Both murine and humanized antibodies are provided.
FI955261A 1993-05-04 1995-11-02 P-selectin antibodies and their use FI955261A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/US1993/004274 WO1993021956A1 (en) 1992-05-05 1993-05-04 Antibodies to p-selectin and their uses
US5729293A 1993-05-05 1993-05-05
US08/202,047 US5800815A (en) 1903-05-05 1994-02-25 Antibodies to P-selectin and their uses
PCT/US1994/004935 WO1994025067A1 (en) 1993-05-04 1994-05-04 Antibodies to p-selectin and their uses

Publications (2)

Publication Number Publication Date
FI955261A0 true FI955261A0 (en) 1995-11-02
FI955261A FI955261A (en) 1996-01-03

Family

ID=27369213

Family Applications (1)

Application Number Title Priority Date Filing Date
FI955261A FI955261A (en) 1993-05-04 1995-11-02 P-selectin antibodies and their use

Country Status (3)

Country Link
EP (1) EP0804235A4 (en)
FI (1) FI955261A (en)
WO (1) WO1994025067A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040942A1 (en) * 1995-06-07 1996-12-19 Cytel Corporation Humanized antibodies to e-selectin
WO1997000956A1 (en) * 1995-06-20 1997-01-09 Trustees Of Boston University Hypoxia-responsive adhesion molecules, specific antibodies, and their uses
AU9603398A (en) * 1997-10-07 1999-04-27 Centocor Inc. Diagnosis of thrombotic events by detecting p-selectin
AU2012200852B2 (en) * 2004-04-13 2012-10-18 F. Hoffmann-La Roche Ag Anti-P-selectin antibodies
CA2885854C (en) * 2004-04-13 2017-02-21 F. Hoffmann-La Roche Ag Anti-p-selectin antibodies
US20110212096A1 (en) 2006-12-01 2011-09-01 Scott Rollins Anti-p-selectin antibodies and methods of their use and identification
US8945565B2 (en) 2006-12-01 2015-02-03 Selexys Pharmaceuticals Corporation Methods of treating inflammatory or thrombotic conditions with anti-P-selectin antibodies
EP3501538A1 (en) 2006-12-01 2019-06-26 Novartis AG Anti-p-selectin antibodies and methods of using the same to treat inflammatory diseases
AU2008309934B2 (en) * 2007-10-12 2014-03-06 F. Hoffmann-La Roche Ag Protein expression from multiple nucleic acids
WO2019025847A1 (en) 2017-08-04 2019-02-07 Novartis Ag Treatment regimens
WO2019171326A1 (en) 2018-03-08 2019-09-12 Novartis Ag Use of an anti-p-selectin antibody
AU2020289364A1 (en) 2019-06-07 2022-01-06 Novartis Ag Use of an anti-P-selectin antibody
US20220324983A1 (en) 2019-08-08 2022-10-13 Novartis Ag Use of the anti-p-selectin antibody crizanlizumab for treating sickle cell nephropathy and chronic kidney disease associated with sickle cell disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
ES2097765T3 (en) * 1989-10-20 1997-04-16 New England Medical Center Inc A PADGEM INTERMEDIATED CELL LINKING INHIBITION SYSTEM.
JP4124480B2 (en) * 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド Immunoglobulin variants
DE69332881T2 (en) * 1992-05-05 2004-01-29 Aeres Biomedical Ltd ANTIBODIES AGAINST P-SELECTIN AND THEIR USE

Also Published As

Publication number Publication date
EP0804235A1 (en) 1997-11-05
EP0804235A4 (en) 2001-09-19
FI955261A (en) 1996-01-03
WO1994025067A1 (en) 1994-11-10

Similar Documents

Publication Publication Date Title
FI955261A (en) P-selectin antibodies and their use
ES2102196T3 (en) PERIPHERIALIZATION OF HEMATOPOYETIC PLURIPOTENTIAL CELLS.
BR9707049A (en) Anticoagulant agents usable in the treatment of thrombosis
ATE439137T1 (en) TREATMENT OF HEMATOLOGICAL DISORDERS
MX9602971A (en) Humanized antibodies against leukocyte adhesion molecule vla-4
DE122009000012I1 (en) Substituted pyrazolylbenzenesulfonamides for the treatment of inflammation.
ID29393A (en) COMPOSITION OF CANCER TREATMENT AND METHOD OF USING NATURAL PLANT ESENSIL OILS
NO982062L (en) Humanized antibodies to human gp39, compositions containing them, and therapeutic use thereof
DK0705100T3 (en) Therapeutically substituted guanidines
FI941826A (en) Methods and compositions for the prevention and / or therapeutic treatment of organ hypofunction
ATE220329T1 (en) COMPOSITION CONTAINING BRADYKININ FOR SELECTIVE OPENING OF ABNORMAL BRAIN TISSUE CAPILLARIES
FI943728A (en) New aminoacetyl mercapto derivatives useful as inhibitors of enkephalinase and ACE
DE69128543T2 (en) MONOCLONAL ANTIBODIES OF THE MOUSE
SE8605295D0 (en) MONOCLONAL ANTIBODIES CROSS-REACTIVE AND CROSSPROTECTIVE AGAINST P. AERUGINOSA SEROTYPES
DE60229406D1 (en) PROCESS FOR TREATING OR PREVENTING VASCULAR INFLAMMATION WITH STEROL ABSORBENT INHIBITOR (DE)
GB9009106D0 (en) Processes and intermediates for synthetic antibody derivatives
DE69405919D1 (en) Compositions for the treatment of keratin fibers
ATE283044T1 (en) COMPACTIN FOR THE TREATMENT OF INFLAMMATION
GR3018304T3 (en) Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4h-pyran-4-ones.
ES2088128T3 (en) ACAT INHIBITOR AMINOSULFONILUREAS.
AU6633694A (en) Novel methods and compositions for the treatment of (ras)-activated cancer with heterotypic anti-(raf) antisense oligonucleotides
IT1208776B (en) COMPOUND FOR THE TREATMENT OF HYPOOVARISM AND MEDICINAL COMPOSITION THAT CONTAINS IT
CA2162149A1 (en) Antibodies to p-selectin and their uses
BG100863A (en) Fibrin-specifil antibody and its use as an antithrombotic agent
GR3031095T3 (en) 3-ALKYLOXY-, ARYLOXY-, OR ARYLALKYLOXYBENZO b]THIOPHENE-2-CARBOXAMIDES AS INHIBITORS OF CELL ADHESION.

Legal Events

Date Code Title Description
FD Application lapsed